ReviewAmerican journal of nuclear medicine and molecular imaging2021
A review of advances in the last decade on targeted cancer therapy using
Review in American journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Dose-Dependent Cellular Phenotypic Change Induced byBiomedicines · 2025Article
- Enhancing the radionuclide theranostic concept through the radiohybrid approach.RSC medicinal chemistry · 2025Review
- Improvement of End-of-Synthesis Radiochemical Purity ofPharmaceutics · 2024Article
- Comparison of the dosimetry and cell survival effect ofEJNMMI physics · 2024Article
- Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [European journal of nuclear medicine and molecular imaging · 2024Article
- Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm.Chemical & biomedical imaging · 2024Review
- Emerging role of electrochemistry in radiochemical separation of medically important radiometals: state of the art.American journal of nuclear medicine and molecular imaging · 2024Review
- Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues.Current oncology (Toronto, Ont.) · 2023Review
- Optimization ofEJNMMI radiopharmacy and chemistry · 2023Article
- Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals.Pharmaceutics · 2023Review
- Radiolysis-Associated Decrease in Radiochemical Purity ofMolecules (Basel, Switzerland) · 2023Article
- Case report: 177Lu DOTA-TATE: a new scheme for the treatment of prostate neuroendocrine cancer.Frontiers in oncology · 2023Article
- [Pharmaceuticals (Basel, Switzerland) · 2022Review
- Advances inPharmaceutics · 2022Review
- Nanotechnology-Assisted Cell Tracking.Nanomaterials (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lutetium-177 [T½ = 6.76 d; E
Indexed as
Identifiers
35003885PMC8727880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.